BNB Reserve Company Welcomes New Member! The US stock pharmaceutical company Liminatus Pharma, originally focused on cancer immunotherapy, released an announcement, declaring the establishment of an "American BNB Strategy" subsidiary, planning to use up to 500 million dollars for long-term BNB investment and holding.
Why Traditional Biotech is Betting on BNB
According to the press release, Liminatus Pharma's CEO Chris Kim highlighted three core reasons explaining why they chose to bet on BNB: First, BNB Chain's technology and global user base have formed a network effect; second, Binance's Launchpool and staking mechanisms provide stable continuous returns; third, BNB's overall ecosystem establishes a clear value bridge between decentralized finance (DeFi) and real-world applications. He stated directly in the telephone conference:
"This is not short-term speculation. We believe in BNB's long-term growth potential, which can enhance the company's capital efficiency and provide shareholders additional returns beyond our drug research and development business."
Risk Management Behind 500 Million Dollars
It is worth noting that 500 million dollars is not a small amount of funds. Therefore, Liminatus Pharma stated that they will use Ceffu's institutional-level custody service and adopt a phased investment approach to reduce risks from market volatility and compliance issues.
Meanwhile, in their internal planning, Liminatus Pharma has also set up three mechanisms: staged fund release, dynamic position limits tied to cash flow, and quarterly board reviews.
LIMN Rises 4.3% Pre-market
According to Google Finance data, possibly influenced by this news, Liminatus Pharma's stock slightly rose before the US market opening, with an increase of about 4.3%, temporarily reporting a pre-market stock price of 9.09 dollars, with a market value of approximately 227 million dollars.
